IRMD vs NVCR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IRMD · IRadimed$81.02 ▼ 0.30%
NVCR · Novocure$10.71 ▲ 0.19%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IRMD -4.4%
- NVCR -5.6%
Head to head
| Metric | IRMD | NVCR |
|---|---|---|
| Price | $81.02 | $10.71 |
| Change today | ▼ 0.30% | ▲ 0.19% |
| Market cap | $1.04B | $1.25B |
| Return, 3 months | -8.0% | -36.1% |
| Return, year to date | -16.2% | -17.2% |
| Return, 1 year | -2.8% | -10.4% |
| P/E (TTM) | 43.3 | – |
| P/B | 9.7 | 3.6 |
| P/E percentile vs own 5y | 69th | 61st |
| Dividend yield | 0.95% | – |
| Revenue growth (YoY, latest qtr) | +14.2% | +15.7% |
| Net profit growth (YoY) | +16.7% | +72.0% |
| Gross margin | 75.5% | 77.0% |
| Operating margin | 32.3% | -17.2% |
| Net margin | 26.8% | -16.8% |
| Return on equity | 23.4% | -35.2% |
| Analyst target vs. price | +48.1% | +149.0% |
| Analyst buy share | 0% | 100% |
| RSI (14) | 49 | 28 |
| 30-day volatility | 47.9% | 60.1% |
| Max drawdown, 1 year | -26.7% | -46.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NVCR is the largest of the group by market value.
- IRMD has returned the most over the past year.
- NVCR is growing revenue fastest.
- IRMD keeps the most profit per dollar of sales.
- IRMD has been the calmest stock over the last 30 days.